MSI 511

Drug Profile

MSI 511

Latest Information Update: 14 Aug 2007

Price : $50

At a glance

  • Originator Genaera Corporation
  • Developer Genaera Corporation; Novartis
  • Class Antineoplastics; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Aug 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 14 Aug 2007 Discontinued - Preclinical for Cancer in Switzerland (unspecified route)
  • 14 Jul 1998 No-Development-Reported for Cancer in Switzerland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top